Trial · NCT00506142
Safety and Efficacy of Marqibo in Metastatic Malignant Uveal Melanoma
NCT00506142, Phase 2, Completed, Spectrum Pharmaceuticals, Inc; results first posted 2019-11-27
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Safety and Efficacy of Marqibo in Metastatic Malignant Uveal Melanoma. Trials, record NCT00506142. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00506142
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Safety and Efficacy of Marqibo in Metastatic Malignant Uveal Melanoma
- NCT number
- NCT00506142
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 54 participants, actual
- Lead sponsor
- Spectrum Pharmaceuticals, Inc
- Conditions
- Metastatic Malignant Uveal Melanoma
- Interventions
- Marqibo® (vincristine sulfate liposomes injection)
- First posted
- 2007-07-25
- Last updated
- 2019-12-11
- Results first posted
- 2019-11-27
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Disease Control Rate | 1 year | Proportion of patients whose best overall response is complete response (CR), partial response (PR), or stable disease (SD) |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Disease Control Rate | 1 year | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Disease Control Rate | Cohort 1 | 18 | Participants | ||
| Disease Control Rate | Cohort 2 | 8 | Participants |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Cohort 1 | 35 | |
| Overall Study | STARTED | Cohort 2 | 19 | |
| Overall Study | COMPLETED | Cohort 1 | 0 | |
| Overall Study | COMPLETED | Cohort 2 | 0 | |
| Overall Study | NOT COMPLETED | Cohort 1 | 35 | |
| Overall Study | NOT COMPLETED | Cohort 2 | 19 |
Source ClinicalTrials.gov
Adverse events294
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | ANAEMIA | Blood and lymphatic system disorders | Cohort 1 | 9 | 35 | 15 |
| other | ANAEMIA | Blood and lymphatic system disorders | Cohort 2 | 4 | 19 | 9 |
| other | LEUKOPENIA | Blood and lymphatic system disorders | Cohort 1 | 1 | 35 | 1 |
| other | LEUKOPENIA | Blood and lymphatic system disorders | Cohort 2 | 2 | 19 | 2 |
| other | THROMBOCYTOPENIA | Blood and lymphatic system disorders | Cohort 1 | 2 | 35 | 4 |
| other | THROMBOCYTOPENIA | Blood and lymphatic system disorders | Cohort 2 | 2 | 19 | 3 |
| other | CARDIAC FAILURE CONGESTIVE | Cardiac disorders | Cohort 1 | 0 | 35 | 0 |
| other | CARDIAC FAILURE CONGESTIVE | Cardiac disorders | Cohort 2 | 1 | 19 | 1 |
| other | SINUS TACHYCARDIA | Cardiac disorders | Cohort 1 | 0 | 35 | 0 |
| other | SINUS TACHYCARDIA | Cardiac disorders | Cohort 2 | 2 | 19 | 2 |
1 to 10 of 294Source ClinicalTrials.gov
See all 294 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Cohort 1 | ||
| Total, all-cause mortality | Cohort 2 | ||
| Total, other adverse events | Cohort 1 | 35 | 35 |
| Total, other adverse events | Cohort 2 | 19 | 19 |
| Total, serious adverse events | Cohort 1 | 15 | 35 |
| Total, serious adverse events | Cohort 2 | 9 | 19 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 20978276 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Cohort 1 vs Cohort 2: Disease Control Rate | Trial comparisons |
| Cohort 1 vs Cohort 2: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00506142
GET https://conductscience.org/api/trials/v1/NCT00506142/events?page=2